|1.||Müller, Thomas: 14 articles (11/2014 - 03/2006)|
|2.||Nyholm, Dag: 9 articles (04/2013 - 10/2006)|
|3.||Chatamra, Krai: 8 articles (09/2015 - 03/2013)|
|4.||Hauser, Robert A: 8 articles (04/2015 - 09/2002)|
|5.||Muhlack, Siegfried: 8 articles (11/2014 - 03/2006)|
|6.||Stocchi, Fabrizio: 7 articles (01/2015 - 06/2005)|
|7.||Poewe, Werner: 6 articles (12/2015 - 07/2010)|
|8.||Antonini, Angelo: 6 articles (09/2015 - 07/2009)|
|9.||Odin, Per: 6 articles (04/2015 - 07/2009)|
|10.||Nyholm, D: 6 articles (12/2012 - 01/2005)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/2004 - "The efficacy of domestic drug tremonorm (levadopa-carbidopa) for Parkinson's disease (PD) treatment was studied. "
01/01/1973 - "A double-blind controlled study of MK-486 in Parkinson's disease."
07/11/2012 - "200mg LD/50mg carbidopa (CD) were administered to 13 patients with Parkinson's disease under standardised conditions. "
10/01/2009 - "Patients with Parkinson's disease (PD) received on two consecutive days in a standardised fashion one single dose of 200 mg retarded release LD/carbidopa (CD) or of 150 mg LD/CD/EN, since both were shown to have simultaneous pharmacokinetic LD behaviour. "
10/01/2006 - "Not optimum treated hospitalised patients with Parkinson's disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting. "
12/01/1996 - "Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation."
01/01/2010 - "Administration of aplindore (1.0 mg/kg p.o.) in combination with L-dopa (2.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) did not inhibit the reversal of motor deficits but improved motor disability and increased both locomotor activity and dyskinesia expression equivalent to that produced by L-dopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.). "
03/01/2005 - "Administration of L-dopa (12.5 mg/kg p.o.) plus carbidopa twice daily produced fluctuating improvement in motor behavior coupled with dyskinesia. "
09/01/2015 - "Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. "
08/01/2015 - "However, chronic treatment with a combination of Levodopa plus carbidopa has been demonstrated to cause a major complication, namely abnormal involuntary movements. "
|3.||Parkinsonian Disorders (Parkinsonism)
02/01/1977 - "[Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid]."
10/01/1978 - "Need for uncombined carbidopa to treat parkinsonism."
07/01/1990 - "1. We have used gait analysis to investigate the efficacy of maintenance therapy with a levodopa/carbidopa combination in patients with idiopathic Parkinsonism, who do not have overt fluctuations in control in relation to administration of medication. "
03/01/2014 - "In patients with CBS and PSPS, parkinsonism is treated with levodopa/carbidopa. "
10/01/2003 - "Levodopa-carbidopa combinations should be considered for treatment of parkinsonism. "
|4.||Myoclonus (Nocturnal Myoclonus)
12/01/1982 - "This rank order of potency differed from that observed for the order of potency of these drugs in inhibiting the myoclonus induced by L-5-hydroxytryptophan (5HTP) plus carbidopa in guinea-pigs (Luscombe, Jenner and Marsden, Neuropharmacology, 1981), perhaps indicating involvement of pharmacologically distinct indoleamine receptors. "
06/01/1980 - "Six patients with myoclonus of varying cause were treated with L-5-hydroxytryptophan (L-5-HTP) and carbidopa. "
06/01/1980 - "Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations."
01/01/1976 - "L-5-HTP with carbidopa dramatically decreased the frequency and intensity of myoclonus, particularly in those patients with a diagnosis of postanoxic intention myoclonus. "
02/01/1975 - "Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486."
|5.||Amblyopia (Lazy Eye)
07/01/1995 - "The present study confirms previous findings of improvement in visual function in amblyopia after levodopa/carbidopa administration. "
03/01/2009 - "Levodopa/carbidopa improves visual acuity in patients with amblyopia and maintains improved visual acuity, especially in patients younger than 8 years."
11/01/1993 - "To determine the tolerability and efficacy of levodopa/carbidopa combined with occlusion therapy for childhood amblyopia, a double-masked placebo-controlled randomized longitudinal study was performed on 10 amblyopic children between 6 and 14 years of age. "
09/01/1992 - "A pilot study was undertaken to address the tolerance and efficacy of levodopa/carbidopa treatment for amblyopia in older amblyopic children who failed to respond to conventional occlusion therapy. "
12/01/2002 - "To study the role of levodopa-carbidopa in supplementing occlusion therapy in older children with strabismic or anisometropic amblyopia. "
|1.||Levodopa (L Dopa)
|2.||levodopa drug combination carbidopa (Nakom)
|3.||5-Hydroxytryptophan (5 Hydroxytryptophan)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Gastric Bypass (Roux-en-Y Gastric Bypass)